This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Q3 Earnings Top, Diagnostic Test Sales Solid
by Zacks Equity Research
In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.
Thermo Fisher (TMO) Q3 Earnings Beat on Life Sciences Sales
by Zacks Equity Research
Significant COVID-19 led business expansions, as well as Thermo Fisher's (TMO) base business growth contribute to a stunning Q3 performance.
The Zacks Analyst Blog Highlights: Zoom Video, Entegris, Copart, Insulet and Intuit
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Zoom Video, Entegris, Copart, Insulet and Intuit
HEXO in Focus: Stock Moves 5.2% Higher
by Zacks Equity Research
HEXO saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Nasdaq Set to Outperform 2019 on Digitization Push: 5 Picks
by Nalak Das
This year, the technology sector is leading the V-shaped recovery from the unprecedented health-hazard-led economic devastation.
Abbott's Libre 3 Receives CE Mark, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) environment-friendly next-generation FreeStyle Libre 3 system aims to provide a better quality of life to diabetics in Europe at the same affordable price of previous systems.
Insulet (PODD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.
4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.
Insulet's Omnipod DASH Shines, New Omnipod Uptake Slows Down
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation of the Omnipod 5 launch in 2021.
Why Is Insulet (PODD) Down 7.1% Since Last Earnings Report?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insulet (PODD) Banks on Omnipod Uptake Amid Coronavirus Woes
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Insulet (PODD) Q2 Earnings Beat Estimates, 2020 View Up
by Zacks Equity Research
Insulet's (PODD) total Omnipod product line comes up with record revenue growth.
Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 2300.00% and 6.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Insulet (PODD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments
Insulet (PODD) Q1 Earnings Lag Estimates, Margins Decline
by Zacks Equity Research
Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.
Insulet (PODD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -50.00% and 4.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on May 7: BDX, ABC & More
by Trina Mukherjee
Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.
Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PayPal, International Business Machines, Fresenius Medical Care, Laboratory Corp. of America and Insulet
Top Stock Reports for PayPal, IBM & Fresenius Medical
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), International Business Machines (IBM) and Fresenius Medical Care (FMS).
3 MedTech Stocks Likely to Have Braved Coronavirus Blow in Q1
by Sriparna Ghosal
Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.
Insulet (PODD) Down 7.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Insulet (PODD) Stock Now
by Zacks Equity Research
Investors remain confident in Insulet (PODD) stock on solid prospects.
Insulet Rides on DexCom Pact, Omnipod's Wider Market Reach
by Zacks Equity Research
Insulet (PODD) plans to expand Omnipod DASH across Europe and Canada, further uplifting market sentiment.